Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Breast Cancer Diagnosis
Interventions: Fine needle aspiration, Cancer Detection cartridge; Procedure · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Lutherville-Timonium, Maryland

Conditions: Melanoma
Interventions: Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tumor Necrosis Factor; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Malignant Skin Neoplasm, Metastatic Malignant Soft Tissue Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Skin Neoplasm, Soft Tissue Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Medical Device Usage and Evaluation, Minibeam Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Foot Ulcer
Interventions: Amnio Excel + weekly, Amnio Excel + max every 2 weeks; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline); Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more

Conditions: Breast Cancer
Interventions: Healing Touch, Standard Treatment; Behavioral · Radiation
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 95 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Psoriasis
Interventions: DFD06; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Madera, California • Santa Ana, California • Hialeah, Florida + 5 more

Conditions: Rheumatoid Arthritis
Interventions: JNJ-38518168, Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Breast Cancer
Interventions: filgrastim, cyclophosphamide, megestrol acetate, melphalan, tamoxifen citrate, thiotepa, conventional surgery, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: SLE (Systemic Lupus)
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PITYRIASIS RUBRA PILARIS
Interventions: Cosentyx; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Scottsdale, Arizona • Jacksonville, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Breast Cancer, Metastatic Cancer
Interventions: adenovirus-mediated human interleukin-12; Biological
Lead sponsor: Max Sung; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions: Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY; Combination Product · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more

Conditions: Systemic Sclerosis (SSc)
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more

Conditions: Breast Neoplasms
Interventions: exemestane, sunitinib malate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining method; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more

Conditions: Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis
Interventions: Losartan, Radiation Therapy; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Neuropathy
Interventions: Alpha lipoic acid; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neuroblastoma, Osteosarcoma
Interventions: iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Months and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2044
U.S. locations: 2
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina

Conditions: Ichthyosis Vulgaris
Interventions: 146-9251 cream, Vehicle cream; Drug
Lead sponsor: Crown Laboratories, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • Plainfield, Indiana • Metairie, Louisiana + 4 more

Conditions: Warts
Interventions: Cidofovir; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Automated Method for Breast Cancer Detection

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors

Characterization of AmnioExcel Plus in Two Treatment Paradigms

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Healing Touch, Quality of Life, and Immunity During Breast Cancer Treatment

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Losartan in Prevention of Radiation-Induced Heart Failure

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris

Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.